Prestige Consumer 株価情報 (NYSE: PBH)

最新ニュース Prestige Consumer (NYSE:PBH) 株価情報

Prestige Consumer

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer Healthcare Inc

Pathfinder Bancorp Inc

PARAMOUNT BED CO ORD by Paramount Bed Co., Ltd.

Paramount Bed Holdings Co Ltd

PBS Holding Inc

PALIBURG HOLDINGS LTD by PALIBURG HOLDINGS LTD.

In the last three months, 4 analysts have published ratings on Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $98.5, along with a high estimate of $104.00 and a low estimate of $93.00. Marking an increase of 6.2%, the current average surpasses the previous average price target of $92.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1742590848_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Prestige Consumer among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryland Conrad</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$97.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$93.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$104.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Prestige Consumer. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Prestige Consumer compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Prestige Consumer's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Prestige Consumer's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PBH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Prestige Consumer analyst ratings.</a>
<h2>All You Need to Know About Prestige Consumer</h2>
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
<h3>Understanding the Numbers: Prestige Consumer's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Prestige Consumer displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 2.68%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Prestige Consumer's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.02%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.47%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Prestige Consumer's ROA stands out, surpassing industry averages. With an impressive ROA of 1.84%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Prestige Consumer's debt-to-equity ratio is below the industry average at 0.57, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 4 Analysts Discuss Prestige Consumer Stock

CORRECTION: RBC Capital analyst Ryland Conrad maintains Premium Brands Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PBH#TSX">PBH</a>) with a Sector Perform and raises the price target from C$96 to C$97. (Stock Name Change From Prestige Consumer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbh#NYSE">PBH</a>) To (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PBH#TSX">PBH</a>) Premium Brands Holdings.

News

Price Target

TSX:PBH

CORRECTION: RBC Capital Maintains Sector Perform on Premium Brands Hldgs, Raises Price Target to C$97 (Stock Name Change From Prestige Consumer (NYSE:PBH) To (TSX: PBH) Premium Brands Holdings.

RBC Capital analyst Ryland Conrad maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Sector Perform and raises the price target from $96 to $97.

RBC Capital Maintains Sector Perform on Prestige Consumer, Raises Price Target to $97

<h3>Companies Reporting Before The Bell</h3>
• Sunlands Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STG#NYSE">STG</a>) is likely to report earnings for its fourth quarter. 
• Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) is likely to report earnings for its fourth quarter. 
• Sow Good (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOWG#NASDAQ">SOWG</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $5.37 million. 
• Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $1.60 billion. 
• MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) is expected to report earnings for its second quarter. 
• NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is estimated to report quarterly loss at $0.42 per share on revenue of $2.85 billion. 
• 51 Talk Online Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COE#AMEX">COE</a>) is expected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) is projected to report earnings for its fourth quarter. 
• Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) is projected to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BFRI

MBRX

MNSO

SOWG

TIVC

Earnings Scheduled For March 21, 2025

Oppenheimer analyst Rupesh Parikh maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Outperform and raises the price target from $87 to $93.

Oppenheimer Maintains Outperform on Prestige Consumer, Raises Price Target to $93

Canaccord Genuity analyst Susan Anderson maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and raises the price target from $93 to $100.

Canaccord Genuity Maintains Buy on Prestige Consumer, Raises Price Target to $100

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and raises the price target from $95 to $104.

DA Davidson Maintains Buy on Prestige Consumer, Raises Price Target to $104

WIIM

Prestige Consumer Healthcare shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 adjusted EPS guidance above estimates.

Guidance

Prestige Consumer Healthcare Raises FY25 Adj EPS Outlook From $4.40 - $4.46 To $4.50 Vs. $4.44 Est.

Prestige Consumer Healthcare Trims FY25 Revenue outlook From $11.25B - $11.40B To $11.28B - $11.32B Vs. $12.21B Est.

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly adjusted earnings of $1.22 per share which beat the analyst consensus estimate of $1.16 by 5.17 percent. This is a 15.09 percent increase over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $290.32 million which beat the analyst consensus estimate of $286.48 million by 1.34 percent. This is a 2.68 percent increase over sales of $282.74 million the same period last year.

Earnings Beats

Prestige Consumer Q3 Adj $1.22 Beats $1.16 Estimate, Sales $290.32M Beat $286.48M Estimate

AAMI

AFRM

AGCO

AMRK

AMZN

APTV

BILL

CCEC

CIGI

CLFD

CLSK

CRNC

CTLP

DOCS

EMBC

ENTG

EXPE

EXPO

FARM

FBIN

FTNT

GOOS

GPRO

GTES

GTIM

HUBG

IBEX

IDCC

IIIV

ILMN

INTR

KVUE

LADR

LESL

Laboratory Corporation Of America Holdings

LION

LITE

LIVE

LQDT

LSPD

LTRX

MAGN

MATW

MCFT

MCHP

MKTX

MPWR

MSGE

MTSI

Earnings Scheduled For February 6, 2025

Management

Prestige Consumer Healthcare CFO Expands Role To Include Chief Operating Officer Responsibilities

A large exercise of company stock options by Adel Mekhail, EVP at Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) was disclosed in a new SEC filing on November 15, as part of an insider exercise.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001295947/000110465924119387//Archives/edgar/data/1295947/000110465924119387/0001104659-24-119387-index.htm">U.S. Securities and Exchange Commission</a> on Friday revealed that Mekhail, EVP at Prestige Consumer in the Health Care sector, exercised stock options for 5,565 shares of PBH stock. The exercise price of the options was $44.33 per share.
Prestige Consumer shares are trading down 0.0% at $82.79 at the time of this writing on Friday morning. Since the current price is $82.79, this makes Mekhail's 5,565 shares worth $214,029.
<h3>All You Need to Know About Prestige Consumer</h3>
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
<h3>Understanding the Numbers: Prestige Consumer's Finances</h3>
Revenue Growth: Prestige Consumer's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -0.88%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 55.46%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Prestige Consumer's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 1.1.
</li>
</ul>
Debt Management: Prestige Consumer's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.61.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 20.19 is lower than the industry average, implying a discounted valuation for Prestige Consumer's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 3.74, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 14.33, Prestige Consumer presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001295947">Check Out The Full List Of Prestige Consumer's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Options Exercise: Adel Mekhail At Prestige Consumer Realizes $214K

A significant insider transaction involving the exercise of company stock options was reported on November 15, by Christine Sacco, Chief Financial Officer at Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>), as per the latest SEC filing.
What Happened: In an insider options sale disclosed in a Form 4 filing on Friday with the <a href="https://www.sec.gov/Archives/edgar/data/0001295947/000110465924119388//Archives/edgar/data/1295947/000110465924119388/0001104659-24-119388-index.htm">U.S. Securities and Exchange Commission</a>, Sacco, Chief Financial Officer at Prestige Consumer, exercised stock options for 24,686 shares of PBH. The transaction value amounted to $1,289,349.
The Friday morning market activity shows Prestige Consumer shares down by 0.0%, trading at $82.79. This implies a total value of $1,289,349 for Sacco's 24,686 shares.
<h3>All You Need to Know About Prestige Consumer</h3>
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
<h3>Financial Insights: Prestige Consumer</h3>
Revenue Growth: Prestige Consumer's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -0.88%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 55.46%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Prestige Consumer exhibits below-average bottom-line performance with a current EPS of 1.1.
</li>
</ul>
Debt Management: Prestige Consumer's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.61.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 20.19 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 3.74, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Prestige Consumer's EV/EBITDA ratio, lower than industry averages at 14.33, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001295947">Check Out The Full List Of Prestige Consumer's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Christine Sacco At Prestige Consumer Capitalizes: Options Exercised, Resulting In $1.29M

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and maintains $95 price target.

DA Davidson Maintains Buy on Prestige Consumer, Maintains $95 Price Target

"We will continue to execute on our business model that is focused on long-term brand-building and leveraging our cash generation. With this proven strategy and strong balance sheet we are well positioned to maximize shareholder value through disciplined capital deployment," Mr. Lombardi concluded.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Fiscal 2025 Outlook</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td>$1,125 to $1,140 million</td>
</tr>
<tr>
<td>Organic Revenue Growth</td>
<td>Approximately 1%</td>
</tr>
<tr>
<td>Adjusted Diluted E.P.S.</td>
<td>$4.40 to $4.46</td>
</tr>
<tr>
<td>Free Cash Flow</td>
<td>$240 million or more</td>
</tr>
</tbody>
</table>
</figure>

Prestige Consumer Affirms FY25 GAAP EPS Guidance Of $4.40-$4.46 vs $4.49 Est; Sales Of $1.13B-1.14B vs $1.14B Est

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $1.08 by 0.93 percent. This is a 1.87 percent increase over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $283.785 million which beat the analyst consensus estimate of $282.093 million by 0.60 percent. This is a 0.88 percent decrease over sales of $286.316 million the same period last year.

Prestige Consumer Q2 2025 Adj. EPS $1.09 Beats $1.08 Estimate, Sales $283.785M Beat $282.093M Estimate

Jefferies analyst Stephanie Wissink assumes Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Hold rating and raises Price Target to $76.

Initiation

Jefferies Assumes Prestige Consumer at Hold, Raises Price Target to $76

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and raises the price target from $93 to $95.

DA Davidson Maintains Buy on Prestige Consumer, Raises Price Target to $95

Press Releases

Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference

Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results

Prestige Consumer Healthcare Inc. Reports First Quarter Fiscal 2025 Results

Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference

Prestige Consumer Healthcare to Release Fiscal 2025 Second Quarter Earnings Results

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2025 Results

Prestige Consumer Healthcare Inc. Expands CFO Christine Sacco's Role to Include Chief Operating Officer Responsibilities

Prestige Consumer Healthcare Announces Fiscal 2025 Third Quarter Earnings Results Date and ICR Conference Presentation

Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook

Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Prestige Consumer

ニュース

最新ニュース Prestige Consumer (NYSE:PBH) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル